subject area of

• A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma  Academic Article
• A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design  Academic Article
• A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen  Academic Article
• A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35  Academic Article
• A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients  Academic Article
• A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma  Academic Article
• A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: Synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation  Academic Article
• A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme  Academic Article
• ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling  Academic Article
• Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells  Academic Article
• Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial- mesenchymal status and Tumor-Associated immune cytolytic activity  Academic Article
• An HLA-A2 polyepitope vaccine for melanoma immunotherapy  Academic Article
• An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma  Academic Article
• Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): A case report and review of the literature  Academic Article
• Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guerin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma  Academic Article
• B Cells and Antibody Production in Melanoma  Academic Article
• BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival  Academic Article
• BRAF V600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells  Academic Article
• BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage  Academic Article
• Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment  Academic Article
• Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients  Academic Article
• Brief report: Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile  Academic Article
• Cancer evolution during immunotherapy  Academic Article
• Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate  Academic Article
• Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells  Academic Article
• Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces  Academic Article
• Cardiac metastases from malignant melanoma  Academic Article
• Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma  Academic Article
• Characterising the phenotypic evolution of circulating tumour cells during treatment  Academic Article
• Characteristics of pyrexia in BRAF V600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial  Academic Article
• Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination  Academic Article
• Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial  Academic Article
• Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma  Academic Article
• Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma  Academic Article
• Clinical promise of tumour immunology  Academic Article
• Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT  Academic Article
• Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma  Academic Article
• Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies  Academic Article
• Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF V600 -mutant melanoma experiencing progression with single-agent BRAF inhibitor  Academic Article
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations  Academic Article
• Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells  Academic Article
• Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents  Academic Article
• Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy  Case Study
• Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens  Academic Article
• Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance  Academic Article
• Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens  Academic Article
• Discovery of [18F]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: A Melanoma Positron Emission Tomography Imaging Radiotracer with High Tumor to Body Contrast Ratio and Rapid Renal Clearance  Academic Article
• Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade  Academic Article
• Distinct Clinical and Pathological Features Are Associated with the BRAFT1799A(V600E) Mutation in Primary Melanoma  Academic Article
• Early Growth Response Gene 1 (EGR1) Regulates Heparanase Gene Transcription in Tumor Cells  Academic Article
• Effect of thymidine analogs on tyrosinase activity and mRNA accumulation in mouse melanoma cells  Academic Article
• Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program  Academic Article
• Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy  Academic Article
• Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases  Academic Article
• Evolving role of tumor antigens for future melanoma therapies  Academic Article
• Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma  Academic Article
• FOXP3 is not mutated in human melanoma  Academic Article
• FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.  Academic Article
• Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients’ sera using short overlapping peptides and full-length recombinant protein  Academic Article
• First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors  Academic Article
• Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody  Academic Article
• Frequent MAGE Mutations in Human Melanoma  Academic Article
• Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli  Academic Article
• Genomic analysis of circulating tumor DNA using a melanoma-specific UltraSEEK oncogene panel  Academic Article
• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients  Academic Article
• Heat Shock Protein Levels Are Not Elevated in Heat-Resistant B16 Melanoma Cells  Academic Article
• Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM  Academic Article
• High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance  Academic Article
• Identifying and targeting determinants of melanoma cellular invasion  Academic Article
• Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment  Academic Article
• Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™  Academic Article
• Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1  Academic Article
• Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma  Academic Article
• Immunotherapy of advanced or metastatic melanoma  Academic Article
• Immunotherapy of melanoma: Targeting defined antigens  Academic Article
• Immunotherapy resistance: the answers lie ahead – not in front – of us  Academic Article
• Impact of 2-Deoxy-2[F-18]Fluoro-d-Glucose Positron Emission Tomography on the Management of Patients with Advanced Melanoma  Academic Article
• Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration  Academic Article
• Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ1  Academic Article
• Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors  Academic Article
• Iterative sorting reveals CD133+and CD133-melanoma cells as phenotypically distinct populations  Academic Article
• Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma  Academic Article
• Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib  Academic Article
• Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines  Academic Article
• Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX (TM) vaccine in patients with advanced melanoma  Academic Article
• MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma  Academic Article
• Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4  Academic Article
• Melanoma vaccines: developments over the past 10 years  Academic Article
• Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations  Academic Article
• Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma  Academic Article
• Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure  Academic Article
• Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro  Academic Article
• NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus  Academic Article
• Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma  Academic Article
• Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial  Academic Article
• Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma  Academic Article
• Novel Imaging Techniques in Melanoma  Academic Article
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy  Academic Article
• Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists  Academic Article
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma  Academic Article
• Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib  Academic Article
• PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation  Academic Article
• Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma  Academic Article
• Periarticular FDG uptake on PET/CT in malignant melanoma-metastatic or misleading?  Case Study
• Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma  Academic Article
• Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma  Academic Article
• Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion  Academic Article
• Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies  Academic Article
• Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma  Academic Article
• Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma  Academic Article
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans  Academic Article
• Regioselective acylation of 3-O-angeloylingenol by Candida antarctica Lipase B  Academic Article
• Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma  Academic Article
• Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’  Letter
• Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma  Academic Article
• Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP  Academic Article
• Role of nuclear medicine in the management of cutaneous malignant melanoma  Academic Article
• SCL gene in human tumors  Academic Article
• Season of diagnosis has no effect on survival from malignant melanoma  Academic Article
• Sentinel node biopsy for melanoma: The medical oncology perspective  Letter
• Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells - Evidence of unique microRNA cargos  Academic Article
• Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma  Academic Article
• Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial  Academic Article
• Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-GD3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts  Academic Article
• Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects  Academic Article
• Standard of care in immunotherapy trials: challenges and considerations  Academic Article
• Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029) : an open-label, phase 1b trial  Academic Article
• Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma  Academic Article
• Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade  Academic Article
• Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells.  Academic Article
• Synthesis and in Vivo Evaluation of [¹²³I]Melanin-Targeted Agents  Academic Article
• Systems analysis identifies miR-29b regulation of invasiveness in melanoma  Academic Article
• Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure  Academic Article
• The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel  Academic Article
• The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression  Academic Article
• The Regulatory T Cell-Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells  Academic Article
• The good, the (not so) bad and the ugly of immune homeostasis in melanoma  Academic Article
• The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.  Academic Article
• The role of BRAF mutations in primary melanoma growth rate and survival  Academic Article
• The self peptide annexin II (208–223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells  Academic Article
• The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma  Academic Article
• The use of dendritic cells in cancer therapy  Academic Article
• Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma  Academic Article
• Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells  Academic Article
• Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage  Academic Article
• Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery  Academic Article
• Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma  Editorial Article
• Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes  Academic Article
• Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.  Academic Article
• Uncertain diagnosis and prognosis in advanced melanoma: a qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies  Academic Article
• Use of [18F]-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy  Academic Article
• Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma  Academic Article
• Whole-genome landscapes of major melanoma subtypes  Academic Article